House approves conference report limiting copay‑accumulator practices for certain drugs

The Indiana House on April 23 approved the conference committee report on House Bill 1604, a measure that adds cost‑sharing protections for certain life‑saving drugs and chronic‑pain medications that lack generic alternatives and requires insurers and pharmacy benefit managers to include third‑party payments in cost‑sharing calculations.

The bill, presented to the House by Representative McGuire, requires pharmacy benefit managers to apply an out‑of‑pocket cap to specified drugs and directs insurers to post average negotiated rates on their websites; the conference report also allows insurers to link to an all‑payer claims database for rate transparency. Representative McGuire described the package to members as “our cost sharing and our bill on the patient’s right to save.”

Why it matters: advocates and several lawmakers said the changes will reduce immediate out‑of‑pocket costs for patients who use manufacturer discount cards or other third‑party assistance. Representative Sheckford told colleagues the amendment contains a practical fix for what are commonly called copay accumulators — practices that, she said, prevented manufacturer assistance from counting toward a patient’s deductible. “That practice basically is insurance companies not allowing people that use a discount card… it wasn’t being applied to their deductible,” she said, explaining that the conference language will cause those payments to count toward a person’s deductible on qualifying drugs.

How it works: under the conference report, where a brand drug lacks a generic (and in some specified life‑saving or chronic‑pain circumstances), patient assistance from manufacturers or third parties must be included in cost‑sharing calculations, reducing the amount a patient ultimately pays before insurance begins paying. Representative Sheckford gave a numeric example: a patient using a $4,000 manufacturer card for a $1,000 monthly drug with a $7,000 deductible would, under current practice, still need to meet the full deductible; under the conference report the $4,000 would count toward the deductible so the patient would pay a reduced amount at the pharmacy.

Limitations and scope: lawmakers said the language does not literally use the term “copay accumulator” but that the effect is to prohibit the practice for the drugs and circumstances specified in the text. The conference report narrows the protections compared with some state laws: it applies to brand drugs without generics and specifically for life‑saving drugs or chronic‑pain treatments, not a blanket ban across all medications.

Vote and next steps: the House adopted the conference committee report by roll call; the clerk recorded 91 ayes and 0 noes and the motion was adopted. The bill will proceed per the legislative calendar for final enactment steps.

Ending: Supporters framed the change as immediate relief for patients taking expensive brand‑name medicines without generics; sponsors asked members to tell constituents that the law will allow third‑party assistance to count toward deductibles in the qualifying cases spelled out in the bill.